KRAS and non-small cell lung carcinoma: Moreover, a subset of KRAS-altered non-Sq NSCLC, representing the biggest alteration subgroup in White and Black patient populations, has long been un-druggable but is now starting to benefit from mutant-specific KRAS G12C inhibitors57.